Lennox-Gastaut Syndrome Treatment: Sequencing Add-On Drugs for Drop Seizures
Eight placebo-controlled trials and a network meta-analysis point to which adjunctive therapy earns an early place — and what to reach for when drop seizures persist.
One-Minute Takeaway
- Lennox-Gastaut syndrome treatment layers add-on antiseizure medications on a resistant baseline; seven agents hold FDA approval, and each reduced drop seizures more than placebo in phase 3 randomized trials — the strongest evidence tier available here.
- High-dose clobazam cut weekly drop seizures by 68.3% versus 12.1% for placebo, and rufinamide lowered tonic-atonic seizure frequency by about 42.5%.
- Cannabidiol reduced monthly drop seizures by 41.9–43.9% across two trials, against 17.2–21.8% for placebo; fenfluramine 0.7 mg/kg/day gave a 19.9-percentage-point greater reduction than placebo.
- No head-to-head trial ranks these drugs directly. A 2025 network meta-analysis placed clobazam and rufinamide among the most effective for drop-seizure control, while flagging cannabidiol, lamotrigine, and high-dose fenfluramine for closer safety monitoring.
- Sequencing stays individualized: efficacy signals, tolerability, drug interactions, and comorbid seizure types all shape which agent comes next.
The Clinical Problem in Lennox-Gastaut Syndrome Treatment
Lennox-Gastaut syndrome (LGS) is a childhood-onset developmental and epileptic encephalopathy. It combines multiple drug-resistant seizure types, a slow spike-and-wave pattern on EEG, and cognitive impairment. Onset is usually before age eight, and the disorder typically persists into adulthood.
Drop seizures — the tonic and atonic attacks that cause a sudden loss of postural tone — are the most disabling feature. A patient can fall without warning, and the resulting head and facial injuries drive much of the day-to-day morbidity. They are also the seizure type most trials use as their primary endpoint.
The injury burden is measurable. In the phase 3 clobazam trial, seizure-related injuries occurred in 8.9% of clobazam-treated patients versus 27.1% of those on placebo. Cutting drop seizures is therefore not only a seizure-count goal but a safety goal.
No single medication controls LGS for most patients, and monotherapy is rarely sufficient. Care is built by adding agents to a background regimen; in one fenfluramine extension cohort, 88% of participants were taking two to four concomitant antiseizure drugs. That reality frames the practical question this review addresses.
Seven add-on drugs carry an FDA indication for seizures associated with LGS: felbamate, lamotrigine, topiramate, rufinamide, clobazam, cannabidiol, and fenfluramine. The clinical challenge is not whether to add a drug, but which to add, in what order, and how to weigh efficacy against tolerability and interactions when the first choice falls short.
Available Add-On Approaches
Every agent below was tested as add-on therapy against placebo in patients already receiving background medication. Because trials differ in era, endpoints, dosing, and how drop seizures were defined, the table reports each result on its own terms rather than as a direct comparison. All figures were confirmed against the primary trial reports.
| Trial (year) | Design | N | Add-on (target dose) | Drop-seizure result vs placebo | Tier |
|---|---|---|---|---|---|
| Felbamate Study Group (1993) | DB RCT | 73 | Felbamate ≤45 mg/kg/d | Atonic seizures fell 34% vs 9% (P=0.01) | V |
| Motte (1997) | DB RCT | 169 | Lamotrigine (titrated) | ≥50% reduction in major seizures: 33% vs 16% (P=0.01) | V |
| Sachdeo (1999) | DB RCT | 98 | Topiramate ~6 mg/kg/d | Drop attacks fell 14.8% vs a 5.1% rise (P=0.041) | V |
| Glauser (2008) | DB RCT | 138 | Rufinamide 45 mg/kg/d | Tonic-atonic seizures fell 42.5% vs a 1.4% rise | V |
| Ng / CONTAIN (2011) | DB RCT | 238 | Clobazam 1.0 mg/kg/d | Weekly drop seizures fell 68.3% vs 12.1% (P<0.0001) | V |
| Devinsky / GWPCARE3 (2018) | DB RCT | 225 | Cannabidiol 20 mg/kg/d | Drop seizures fell 41.9% vs 17.2%; median difference 21.6 pts (95% CI 6.7–34.8; P=0.005) | V |
| Thiele / GWPCARE4 (2018) | DB RCT | 171 | Cannabidiol 20 mg/kg/d | Drop seizures fell 43.9% vs 21.8%; median difference −17.21 (95% CI −30.32 to −4.09; P=0.0135) | V |
| Knupp (2022) | DB RCT | 263 | Fenfluramine 0.7 mg/kg/d | 19.9-pt greater drop reduction vs placebo (P=0.001); ≥50% responders 25% vs 10% | V |
Established Add-Ons: Felbamate, Lamotrigine, and Topiramate
Felbamate was the first agent proven effective in LGS in a controlled trial. In 73 patients, it reduced atonic seizure frequency by 34% against a 9% placebo reduction. Its use is now restricted, because post-marketing surveillance linked it to aplastic anemia and hepatic failure, requiring boxed-warning monitoring.
Lamotrigine followed. In 169 patients, a third achieved at least a 50% reduction in major seizures versus 16% on placebo. It broadened options meaningfully, but the risk of serious rash — including Stevens-Johnson syndrome — mandates slow titration, which delays the time to a useful dose.
Topiramate produced a more modest drop-seizure signal: a 14.8% median reduction against a slight placebo increase. It remains useful, though dose-related cognitive and language adverse effects can limit tolerability in a population already burdened by cognitive impairment.
Modern Standards: Clobazam and Rufinamide
Clobazam produced the largest drop-seizure reduction in this set. In the CONTAIN trial, weekly drop-seizure rates fell in a clear dose-dependent pattern, and 77.6% of high-dose patients reached at least a 50% reduction versus 31.6% on placebo. As a benzodiazepine, its main long-term caveats are sedation and the potential for waning effect.
Rufinamide, a structurally distinct triazole, reduced tonic-atonic seizure frequency by roughly 42.5% while placebo rose slightly. The most common adverse effects were somnolence and vomiting. Its efficacy against the tonic and atonic events that define drop attacks makes it a frequent early choice.
Cannabidiol raises levels of N-desmethylclobazam, the active metabolite of clobazam. A 2020 appraisal questioned how much of cannabidiol’s measured benefit is independent of this interaction, so co-prescription warrants attention to sedation and, where relevant, clobazam dose.
The Newest Options: Cannabidiol and Fenfluramine
Highly purified cannabidiol was tested in two phase 3 trials, GWPCARE3 and GWPCARE4. Both showed monthly drop-seizure reductions in the low-to-mid 40% range versus roughly 17–22% for placebo. Elevated liver aminotransferases were the notable adverse signal, most often when cannabidiol was combined with valproate.
Fenfluramine, already approved in Dravet syndrome, reduced drop seizures at 0.7 mg/kg/day by 19.9 percentage points more than placebo, and it also lowered generalized tonic-clonic seizure frequency — the seizure type most tied to sudden death in epilepsy. No patient developed valvular disease or pulmonary hypertension during the trial, but echocardiographic monitoring remains part of its labeling.
Comparative Analysis: Sequencing Lennox-Gastaut Syndrome Treatment
The central limitation of Lennox-Gastaut syndrome treatment is that no randomized trial pits one add-on directly against another for drop seizures. Every pivotal trial compares a single drug with placebo. Any ranking therefore rests on indirect comparison, cross-trial context, and consensus — not head-to-head data.
A 2025 network meta-analysis pooled 12 randomized trials and 1,445 patients to estimate relative efficacy. For achieving at least a 50% reduction in drop seizures, its ranking placed clobazam 1 mg/kg/day, anterior corpus callosotomy, and rufinamide as the three most effective interventions. For median percentage reduction in drop-seizure frequency, clobazam ranked highest, followed by clobazam at a lower dose and then rufinamide.
Safety pulled in a different direction. The same analysis associated cannabidiol 20 mg/kg/day with the highest likelihood of adverse events, followed closely by fenfluramine 0.7 mg/kg/day. Lamotrigine was ranked most likely to produce serious adverse reactions. Efficacy and tolerability, in other words, do not track together across these agents.
These indirect signals suggest a defensible logic rather than a fixed order. Agents with strong drop-seizure efficacy and manageable monitoring — clobazam and rufinamide — often earn early consideration. Cannabidiol and fenfluramine add value where generalized tonic-clonic seizures coexist or where earlier agents fail, weighed against their monitoring demands. Felbamate is generally reserved because of its toxicity profile, and lamotrigine’s slow titration shapes when it can realistically contribute.
Quality and Consistency of the Evidence
The evidence is strongest for the narrow question each trial asked — does this drug reduce drop seizures more than placebo — and weakest for the comparative question clinicians actually face.
- Single-agent efficacy versus placeboStrong evidence supports a drop-seizure benefit for each approved add-on, from multiple double-blind randomized trials with consistent direction of effect.
- Magnitude of benefitEvidence suggests clinically meaningful reductions, but effect sizes vary and placebo responses were large (17–22% in the newer trials), which tempers interpretation of any single percentage.
- Cross-trial comparabilityInsufficient evidence to compare agents directly: trials differ in baseline seizure frequency, endpoints (weekly vs monthly; drop vs tonic-atonic), eras, and concomitant drugs.
- Sequencing and orderingInsufficient evidence to determine an optimal sequence; ranking derives from indirect network comparison and expert consensus, not randomized head-to-head trials.
- Durability of responsePreliminary-to-moderate evidence from open-label extensions suggests maintained drop-seizure reduction over months to years, but without a controlled comparator.
What the Evidence Does Not Show
No direct comparisons. Not one randomized trial compares two add-on drugs against each other for drop seizures, so claims that one agent outperforms another rest on indirect inference.
Sequencing is not trial-validated. The order in which agents should be added has never been tested in a randomized design; algorithms reflect consensus and pooled ranking.
The newest candidate is inconclusive. A phase 3 trial of perampanel (Study 338) was terminated early because of recruitment problems and the COVID-19 pandemic, leaving its drop-seizure effect uncertain and at high risk of bias.
Hard outcomes are largely unaddressed. Effects on cognition, development, and mortality — including sudden unexpected death in epilepsy — are not established by these seizure-count trials.
The cannabidiol–clobazam question is open. Whether cannabidiol’s benefit is fully independent of its interaction with clobazam has not been resolved.
Practical Implications
The evidence supports treating drug choice as an individualized decision rather than a ranked list to work through. Seizure semiology, existing regimen, interaction potential, and the capacity for safety monitoring all carry weight alongside raw efficacy.
For drop seizures specifically, the data support giving early consideration to agents with the clearest drop-seizure signal and workable monitoring — clobazam and rufinamide feature prominently in both the trials and the pooled ranking. Where generalized tonic-clonic seizures coexist, the evidence supports considering fenfluramine or cannabidiol, provided the required cardiac or hepatic monitoring is feasible.
Tolerability often decides sequencing in practice. Lamotrigine’s mandatory slow titration, topiramate’s cognitive effects, felbamate’s hematologic and hepatic monitoring, and benzodiazepine sedation with clobazam each shape when and whether an agent fits a given patient. Matching the drug to the patient’s comorbidities and the family’s monitoring capacity is as consequential as the effect size on paper.
Finally, the large placebo responses seen in the newer trials argue for judging any add-on against a patient’s own diary-based baseline over an adequate interval, rather than expecting the headline trial percentage in every case.
Evidence Grade and Bottom Line
Overall grade: Moderate for single-agent efficacy · Low for sequencingEach approved add-on has moderate-to-strong randomized evidence for reducing drop seizures versus placebo. The comparative question — which agent, and in what order — has only low-certainty, indirect evidence behind it.
- Clobazam and rufinamide show the strongest and most consistent drop-seizure effects across trials and pooled ranking.
- Cannabidiol and fenfluramine are well-supported newer options, particularly when generalized tonic-clonic seizures coexist, balanced against monitoring needs.
- Felbamate and lamotrigine remain effective but are constrained by safety and titration requirements.
- Because no head-to-head data exist, sequencing should stay individualized and revisited against the patient’s own seizure diary.
Article Information and References
- Zhu Z, Zhang Z, Xiao W, Wang C, Liang R. Efficacy and safety of pharmacological and non-pharmacological therapies in Lennox-Gastaut syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2025;16:1522543. DOI: https://doi.org/10.3389/fphar.2025.1522543
- Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021;4(4):CD003277. DOI: https://doi.org/10.1002/14651858.CD003277.pub4
- Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897. DOI: https://doi.org/10.1056/NEJMoa1714631
- Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–1096. DOI: https://doi.org/10.1016/S0140-6736(18)30136-3
- Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–564. DOI: https://doi.org/10.1001/jamaneurol.2022.0829
- Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–1481. DOI: https://doi.org/10.1212/WNL.0b013e318232de76
- Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950–1958. DOI: https://doi.org/10.1212/01.wnl.0000303813.95800.0d
- Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology. 1999;52(9):1882–1887. DOI: https://doi.org/10.1212/WNL.52.9.1882
- Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med. 1997;337(25):1807–1812. DOI: https://doi.org/10.1056/NEJM199712183372504
- The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328(1):29–33. DOI: https://doi.org/10.1056/NEJM199301073280105
- Vossler DG, Porter BE, Kira R, et al. Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: a randomized trial. Epilepsia. 2025;66(2):379–393. DOI: https://doi.org/10.1111/epi.18193